<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01526694</url>
  </required_header>
  <id_info>
    <org_study_id>BDT-01-2011</org_study_id>
    <nct_id>NCT01526694</nct_id>
  </id_info>
  <brief_title>Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs</brief_title>
  <official_title>Phase II Multicenter Clinical Trial to Investigate the Efficacy and Safety of Bendamustine, Dexamethasone and Thalidomide in Relapsed or Refractory Multiple Myeloma Patients After Treatment With Lenalidomide and Bortezomib or Which Are Ineligible to One of These Drugs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera di Bolzano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mundipharma Pte Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Ospedaliera di Bolzano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter phase II trial designed to determine efficacy and safety
      of a combination chemotherapy consisting of Bendamustine + Dexamethasone + Thalidomide in
      patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib
      or which are ineligible to one of these drugs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assessment of response</measure>
    <time_frame>18 months</time_frame>
    <description>To evaluate the efficacy of BDT in relapsed or refractory multiple myeloma as measured by the rate of responses (blood and urine tests, X-ray, BMA and BMB, Karnofsky PS)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>safety assessment</measure>
    <time_frame>18 months</time_frame>
    <description>To assess the tolerability and toxicity in terms of number of participants with Adverse Events (laboratory tests, phyisical examination and ECGs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SURVIVAL</measure>
    <time_frame>18 MONTHS</time_frame>
    <description>Time to treatment failure, overall survival and disease free survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>treatment with BDT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine + Dexamethasone + Thalidomide</intervention_name>
    <description>Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.</description>
    <arm_group_label>treatment with BDT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Understand and voluntarily sign an informed consent form.

          -  Age 18 years at the time of signing the informed consent form.

          -  Life expectancy of at least 3 months

          -  Able to adhere to the study visit schedule and other protocol requirements

          -  Relapsed or refractory active MM (according to the International Myeloma Working Group
             guidelines) after treatments containing bortezomib and lenalidomide or ineligible
             (intolerance or toxicity) to one of these drugs with detectable myeloma protein in
             blood or urine.

          -  Disease free of prior malignancies for at least 5 years.

          -  All previous multiple myeloma treatments, including radiation, cytostatic therapy and
             surgery, must have been discontinued at least 4 weeks prior to treatment in this
             study, except corticosteroids therapy.

          -  ECOG performance status &lt;2 at study entry, unless it is due to MM.

          -  At least the following laboratory findings at the day of treatment start:

          -  Platelet count ≥ 75 x 10^9/L without transfusional support within 7 days.

          -  Neutrophil count &gt; 1.5 x 10^9/L without G-CSF.

          -  Corrected calcium ≤ 14 mg/dL (3.5 mmol/L).

          -  AST: ≤ 2.5 times the normal upper limit.

          -  ALT: ≤ 2.5 times the normal upper limit.

          -  Total bilirubin: ≤ 1.5 times the normal upper limit.

          -  Measured or calculated creatinine clearance of ≥ 20 mL/minute

          -  Women of child bearing potential and male patients whose partner is a woman of child
             bearing potential must be prepared to use two effective methods of contraception both
             before and during protocol treatment, or commit to absolute and continuous
             abstinence.The pregnancy test must be negative 14-28 days and 72 hours before
             treatment start. Only in case of hysterectomy or presence of menopause for at least 24
             consecutive months pregnancy tests as well as contraception are not necessary. Men
             must not father a child for up to 6 months following cessation of treatment and must
             use condoms.

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          -  Pregnant or breast feeding females.

          -  Any condition, including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if he/she were to participate in the study or confounds
             the ability to interpret data from the study.

          -  Patients with contraindications for treatment with bendamustine, dexamethasone and
             thalidomide.

          -  Uncontrolled or severe cardiovascular disease, including myocardial infarction within
             6 months before study entry, New York Heart Association Class III or IV heart failure,
             uncontrolled angina or severe uncontrolled ventricular arrhythmias (≥ Lown 3).

          -  Use of any other experimental drug or therapy within 28 days of baseline.

          -  Known hypersensitivity to thalidomide or purine analogues

          -  Concurrent use of other anti-cancer agents or treatments other stated in this
             treatment plan.

          -  Peripheral neuropathy grade ≥2 according to WHO

          -  Known positive for HIV or infectious hepatitis, type A, B or C.

          -  Major surgery less than 30 days before start of treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergio Cortelazzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera di Bolzano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Mian, MD</last_name>
    <phone>+39 0471 908807</phone>
    <email>michael.mian@asbz.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Hematology and CBMT</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mian, MD</last_name>
      <phone>+39 0471 908807</phone>
      <email>michael.mian@asbz.it</email>
    </contact>
    <investigator>
      <last_name>Sergio Cortelazzo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Mian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Norbert Pescosta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2012</study_first_posted>
  <last_update_submitted>July 14, 2016</last_update_submitted>
  <last_update_submitted_qc>July 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera di Bolzano</investigator_affiliation>
    <investigator_full_name>Michael Mian</investigator_full_name>
    <investigator_title>co-investigator</investigator_title>
  </responsible_party>
  <keyword>relapsed or refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

